Full-Time
Confirmed live in the last 24 hours
Develops RNAi-based therapies for diseases
$58k - $68k/yr
Entry, Junior, Mid
Fitchburg, WI, USA
Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing the genes responsible for them. The company uses RNA interference (RNAi), a natural process that reduces the expression of specific genes, to achieve effective treatment outcomes. This method allows for significant reduction of target genes, which can help stop or reverse the progression of diseases like cystic fibrosis and hepatitis B. Arrowhead stands out from competitors by focusing specifically on RNAi-based therapies and leveraging a strong portfolio of RNA chemistries and delivery methods. The company's goal is to address unmet medical needs and provide new treatment options for genetic disorders, generating revenue through partnerships, licensing agreements, and potential direct sales of approved therapies.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Pasadena, California
Founded
2004
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Paid Vacation
Paid Sick Leave
Mr. Apel joins the company from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis from 2019 through 2024.
Arrowhead Pharmaceuticals launches FCS patient resources on Rare Disease Day.
New Patient Resource Hub: Arrowhead expands its We'll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides
Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.
Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.